Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lomitapide for the treatment of hypercholesterolemia.

Expert opinion on pharmacotherapy - 1 Aug 2017

Berberich Amanda J, Hegele Robert A

Abstract excerpt

INTRODUCTION: Homozygous familial hypercholesterolemia (HoFH) is a serious rare inherited condition that leads to extremely elevated levels of low density lipoprotein cholesterol (LDL-C), and predisposes affected individuals to high risk of atherosclerotic vascular disease. Traditional therapies are largely ineffective in managing the hypercholesterolemia in these patients; diet and regular LDL-apheresis are the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholesterol, LDL
Share to Carrier Proteins
Share to Anticholesteremic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Atherosclerosis

Share to Benzimidazoles

Share to Clinical Trials as Topic

Share to Genotype

Share to Hypercholesterolemia

Source

Identifiers

PMID: 28598687
DOI: 10.1080/14656566.2017.1340941

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lomitapide for the treatment of hypercholesterolemia.PMID 28598687Read ↗

Lomitapide for the management of homozygous familial hypercholesterolemia.Semantic proximity Read ↗

Microsomal transfer protein (MTP) inhibition-a novel approach to the treatment of homozygous hypercholesterolemia.Semantic proximity Read ↗

Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.Semantic proximity Read ↗

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.Semantic proximity Read ↗

Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice.Semantic proximity Read ↗

Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia.Semantic proximity Read ↗

Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia.Semantic proximity Read ↗

MTTP gene variants and lomitapide response in a cohort of patients with homozygous familial hypercholesterolemiaSemantic proximity Read ↗

Lomitapide: A Medication Use Evaluation & a Formulary PerspectiveSemantic proximity Read ↗

Autosomal recessive hypercholesterolemia: update for 2020.Semantic proximity Read ↗

Individual analysis of patients with HoFH participating in a phase 3 trial with lomitapide: The Italian cohort.Semantic proximity Read ↗

MTP Gene Variants and Response to Lomitapide in Patients with Homozygous Familial Hypercholesterolemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.